Acarbose
- Generic Name
- Acarbose
- Brand Names
- Precose
- Drug Type
- Small Molecule
- Chemical Formula
- C25H43NO18
- CAS Number
- 56180-94-0
- Unique Ingredient Identifier
- T58MSI464G
- Background
Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are responsible for the metabolism of complex...
- Indication
Acarbose is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Effect of Acarbose and Mixture of Pioglitazone and Metformin in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2022-11-29
- Target Recruit Count
- 50
- Registration Number
- NCT05629806
- Locations
- 🇨🇳
Nanjing First Hospital, Nanjing Medical Univesity, Nanjing, China
Real-world Study Comparing the Adherence and Effectiveness of Linagliptin vs. Acarbose
- First Posted Date
- 2019-11-29
- Last Posted Date
- 2022-06-23
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 85
- Registration Number
- NCT04180813
- Locations
- 🇨🇳
Huai'an first people's hospital, Huai'an, China
🇨🇳Dongying People's Hospital, Dongying, China
🇨🇳Zhongda Hospital Southeast University, Nanjing, China
Bioequivalence Study for Acarbose/Metformin FDC
- Conditions
- Interventions
- First Posted Date
- 2019-08-22
- Last Posted Date
- 2020-04-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 24
- Registration Number
- NCT04065581
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, China
Effects of Liraglutid, Dapagliflozin and Acarbose on the Cognitive Function, Olfactory Function, and Odor-induced Brain Activation in Overweight/Obese T2DM Patients Controlled Inadequately With Metformin Monotherapy.
- Conditions
- Interventions
- First Posted Date
- 2019-05-23
- Last Posted Date
- 2019-05-23
- Target Recruit Count
- 87
- Registration Number
- NCT03961659
- Locations
- 🇨🇳
at Division of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University, Nanjing, Jiangsu, China
Efficacy and Safety of Alogliptin vs. Acarbose in Chinese Type 2 Diabetes Mellitus (T2DM) Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug Naive
- Conditions
- Interventions
- First Posted Date
- 2019-01-07
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1293
- Registration Number
- NCT03794336
- Locations
- 🇨🇳
CHINA, China, China
Effects of a Dipeptidyl Peptidase-4 Inhibitor Sitagliptininsulin on the Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2018-07-27
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT03602638
Acarbose and Prandial Insulin for the Treatment of Gestational Diabetes Mellitus.
- Conditions
- Interventions
- First Posted Date
- 2017-12-21
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 341
- Registration Number
- NCT03380546
- Locations
- 🇫🇷
Jean Verdier Hospital, Bondy, France
Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy
- Conditions
- Interventions
- First Posted Date
- 2017-12-02
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 384
- Registration Number
- NCT03359837
- Locations
- 🇨🇳
CHINA, China, China
Loose-dose Combination of Acarbose and Metformin for T2DM in Metformin-failure Patients
- Conditions
- Interventions
- First Posted Date
- 2017-11-21
- Last Posted Date
- 2020-08-05
- Lead Sponsor
- Bayer
- Target Recruit Count
- 287
- Registration Number
- NCT03349684
- Locations
- 🇨🇳
The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
🇨🇳Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳Sun Yat-Sen Memorial Hosp. Sun Yat-Sen Univ., Guangzhou, Guangdong, China
A Phase IV Study in Drug-Naive Patients With T2DM in China
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2021-12-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 304
- Registration Number
- NCT03344341
- Locations
- 🇨🇳
Research Site, Yinchuan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.